DIRS.INFO The most relevant business & tech news

☆ China is 'fighting hard', but mainly in the wrong direction: David Roche
▼ + stars: | 2024-10-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChina is 'fighting hard', but mainly in the wrong direction: David RocheDavid Roche of Quantum Strategy says the complexity of the issue in China is not being comprehended by the authorities, and discusses what measures he thinks are needed to "get the economy moving".

Persons: David Roche David Roche Organizations: China, Quantum Locations: China

☆ 13 best hyperpigmentation products for dark skin, according to experts
▼ + stars: | 2024-10-16 | by ( Ashley Morris | Ashley Morris Is An Associate Seo Reporter For Select On Nbc News. | ) www.nbcnews.com time to read: +25 min

I also rounded up a list of the best hyperpigmentation products for dark skin according to their advice and suggestions, along with some of my own personal picks. | How I picked the best hyperpigmentation products for dark skin | The best hyperpigmentation products for dark skin | How to shop for hyperpigmentation products | Why trust NBC Select? How I picked the best hyperpigmentation products for dark skinUsing expert guidance, I rounded up the best hyperpigmentation products for dark skin, including recommendations from the dermatologists I consulted, NBC Select staff picks, and more. Type : Hyperpigmentation products come in a variety of formulas, many of which can be used together in order to better treat discoloration. : Hyperpigmentation products come in a variety of formulas, many of which can be used together in order to better treat discoloration.

Persons: I’ve, Michelle Henry, Hope Mitchell, Nkem, Henry, Ugonabo, Mitchell, ”, Hyperpigmentation, “, ” Mitchell, La, Posay, Cleanser Mitchell, —, Bianca Alvarez, Lindsay Schneider —, I’d, niacinamide, it’s, It’s, Mili Godio, Roche, retinoids “, Retinoids, arbutin, , Patience, TikTok Organizations: Mitchell Dermatology, Union Derm, NBC, La Roche, — NBC, Neutrogena, Facebook, Twitter Locations: Ohio, Union, NYC, La

☆ Everything our editors bought for Amazon October Prime Day 2024
▼ + stars: | 2024-10-10 | by ( Aksha Mittapalli | Aksha Mittapalli Is An Editorial Intern For Select On Nbc News. She Is A Senior At Nyu | Double Majoring In Journalism | ) www.nbcnews.com time to read: +17 min

Whether we're stocking up on familiar favorites or taking advantage of big discounts, NBC Select editors made good use of Prime Day. Below are all the products we added to our carts this October Prime Day. I never don’t have extra bottles in my apartment and I always like to stock up on it during Prime Day. I always buy basics on Prime Day, so this was a no-brainer to throw in my cart last minute. To round up this list, I asked editors what they bought for Prime Day and why they bought each product.

Persons: – Lindsay Schneider, – Mili, La, I’ve, – Cory Fernandez, bobby pins, – Lauren Swanson, they’re, Mili, Zoe Malin, – Rebecca Rodriguez, – Aksha, – Bianca Alvarez, Ana Luisa, Anker, Aksha, – Ella Morrissey, – Nikki Brown, Rosalie Sparaco, It’s comfy, they’ve, – Ashley Morris, – Zoe Malin, – Jordan Bowman, I’m, TikTok Organizations: NBC, La Roche, Apple, Amazon, July’s, Prime, Facebook, Twitter Locations: Poppi

☆ CNBC Daily Open: Fear is the stock killer
▼ + stars: | 2024-10-08 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

Michael M. Santiago | Getty ImagesThis report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. The yield curve inverted in early July 2022 and normalized in early September. It's not inconceivable, then, for investors who take stock in what the yield curve signals to panic a little. But there's an undercurrent of fear that can perhaps run contrary to what some of those numbers are saying.

Persons: Michael M, That's, Jeff Cox, It's, David Roche, Bob Parker, – CNBC's, Lisa Kailai Han, Jesse Pound Organizations: New York Stock Exchange, Santiago, CNBC, Quantum, International Capital Markets Locations: New York City, U.S

☆ CNBC Daily Open: U.S. economy’s fine, but markets driven by fear
▼ + stars: | 2024-10-08 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

Brendan McDermid | ReutersThis report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Markets are back to contending with rising oil prices, inflation possibly reaccelerating, fewer-than-expected rate cuts and potentially even a distant recession. The yield curve inverted in early July 2022 and normalized in early September. It's not inconceivable, then, for investors who take stock in what the yield curve signals to panic a little.

Persons: IXIC, Brendan McDermid, That's, Jeff Cox, It's, David Roche, Bob Parker, – CNBC's, Lisa Kailai Han, Jesse Pound Organizations: New York Stock Exchange, Reuters, CNBC, Quantum, International Capital Markets Locations: U.S

☆ 18 Best Pregnancy-Safe Skin Care in 2024, According to Experts
▼ + stars: | 2024-10-07 | by ( Macaela Mackenzie | ) www.nbcnews.com time to read: +32 min

SKIP AHEAD The best pregnancy-safe skin care products in 2024 | How to shop for pregnancy-safe skin care | Why trust NBC Select? How I picked the best pregnancy-safe skin care productsI asked board-certified dermatologists about common pregnancy skin concerns like dryness and sensitivity and for their recommendations on pregnancy-safe formulas. The best pregnancy-safe skin care products in 2024When you’re pregnant, it may feel like you have to abandon your skin care routine and start new, but experts say that is not always the case. The fragrance-free formula has broad-spectrum protection, which means it keeps your skin safe from both UVA and UVB rays. How to shop for pregnancy-safe skin careWhen shopping for pregnancy-safe skin care, experts say the best approach involves assessing your skin’s changing needs and talking with your doctor about what ingredients you feel comfortable using.

Persons: Sejal Shah, ”, Rachel Nazarian, Erum Ilyas, you’re, Shah, La, Mili Godio, It’s, niacinamide, EltaMD, Posay’s, ceramides, Ilyas, Nazarian, “, Squalane, “ It’s, dullness, There’s, Melasma, you’ve, they’re, retinoids, it’s, “ it’s, Oxybenzone, clary, TikTok Organizations: NBC, Dermatology, Neutrogena’s Hydro, La Roche, American Academy of Dermatology, OB, American College of Obstetricians, Alpha, National Institutes of Health, NIH, Facebook, Twitter Locations: New York, Pennsylvania, erring

☆ No case for more jumbo rate cuts by the Fed, strategists say
▼ + stars: | 2024-10-07 | by ( Holly Ellyatt | ) www.cnbc.com time to read: +4 min

A television broadcasts the Federal Reserve's interest rate cut on the floor of the New York Stock Exchange on Sept. 18, 2024. Roche said the figures made the Fed's "jumbo interest rate cut look silly, populist and panicky." 1 is that [it gives the impression that] the economy is more fragile than it is ... and the economy is fine, thank you very much, and doesn't need jumbo rate cuts," he told CNBC's "Squawk Box Europe." And headline and core inflation will stay above the Fed target of 2%, so the case for aggressive rate cuts [is not there]," he said. "Yes there is a case for modest rate cuts, there is a case for 25 to 50 basis point cuts by January next year, but a case for 50 basis point cut at the next meeting just does not exist," Parker said.

Persons: Michael Nagle, David Roche, Roche, CNBC's, " Roche, Bob Parker, Parker, Dave Pierce Organizations: New York Stock Exchange, Bloomberg, Getty, Federal Reserve, CNBC, Quantum, Federal, Market, International Capital Markets Association, Fed, Global, Capital, Dow Jones Industrial Locations: Israel, U.S

☆ David Roche says misleading 50-basis-point Fed cut will create market instability
▼ + stars: | 2024-10-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche says misleading 50-basis-point Fed cut will create market instabilityDavid Roche, strategist at Quantum Strategy, says the Federal Reserve's initial jumbo cut gives markets the wrong impression that rates will return to rock bottom.

Persons: David Roche Organizations: Quantum

☆ Tadej Pogačar equals one of cycling’s most prestigious feats with world championship win
▼ + stars: | 2024-09-29 | by ( Issy Ronald | ) edition.cnn.com time to read: +2 min

By completing cycling’s “Triple Crown” – as this trio of victories is known – Pogačar joins an exclusive club comprised of just Eddy Merckx, Stephen Roche and Annemiek van Vleuten. This season has confirmed the Slovenian’s status as a generational talent since, unusually for a cyclist, he can win races of almost any length and on different terrains. That includes one-day races like the world championships, which require an explosiveness normally sacrificed by Tour de France contenders in favor of the endurance needed to win a three-week stage race. “After many years fighting for the Tour de France and other races I never had the world championship as a clear goal, but this year everything went smoothly already,” Pogačar said afterward. Zac Williams/Pool/SWpix.com/APAnd the 26-year-old has underlined his complete dominance with the way in which he has won all these races.

Persons: Tadej Pogačar, Pogačar, Eddy Merckx, Stephen Roche, Annemiek van, van Vleuten, hasn’t, Roche, ” Pogačar, “, Zac Williams, France’s Pavel Sivakov –, –, ”, Australia’s Ben O’Connor, Mathieu van der Organizations: CNN, de France, Giro, cycling’s, Triple, Giro d’Italia, Tour de, Tour de France Locations: Switzerland, Australia’s, Netherlands

☆ ‘The Boyfriend,’ Japan’s first same-sex reality show, hopes to normalize LGBTQ romance in the country
▼ + stars: | 2024-09-20 | by ( ) www.nbcnews.com time to read: +6 min

The untroubled July arrival of the country’s first same-sex dating reality show, “The Boyfriend,” on streamer Netflix, may be another sign that normalization of queerness in Japan is on the way. “It’s no different from the familiar reality shows we’ve seen before. The only thing that felt odd or questionable was that, while there have been plenty of heterosexual reality shows, there have been so few featuring same-sex couples, and none in Japan,” casting director Taiki told Variety. The commentators included central host Megumi, an entertainer; drag queen Durian Lollobrigida; Tokui Yoshimi, a veteran of previous reality shows including “Terrace House”; Horan Chiaki; and style diva Thelma Aoyama. “As this was Japan’s first romance reality show featuring male same-sex relationships, it was crucial to have someone from that community in the studio,” Lollobrigida told Variety.

Persons: “, we’ve, ”, Taiki, Dai, Shun, Taehon, inoffensively, Roche, Kimura Hana, Hishida Keisuke, Ota Dai, Durian Lollobrigida, Tokui, Horan Chiaki, Thelma Aoyama, ” Lollobrigida, …, Kitano Takeshi, they’re, ’ Organizations: Netflix, New York Times, Fuji Television, Kyodo Television, Netflix Japan, “, Tokyo Locations: Japan, East Asia, Shinjuku Ni, “ Terrace

☆ Unlikely to see large-scale repatriation of assets back into Japan after Fed's rate cut: Economist
▼ + stars: | 2024-09-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUnlikely to see large-scale repatriation of assets back into Japan after Fed's rate cut: EconomistDavid Roche of Quantum Strategy and Martin Schulz of Fujitsu discuss the effect of Fed rate cuts and repatriation from funds back to Japan.

Persons: David Roche, Martin Schulz Organizations: Quantum, Fujitsu Locations: Japan

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

Though we usually associate acne-prone skin with the more annoying parts of our teenage years, it has become more common in adults. SKIP AHEAD The best products for acne-prone skin | What are the best ingredients for acne-prone skin? The best products for acne-prone skin in 2024The dermatologists I spoke to recommend products with acne-fighting ingredients like salicylic acid, benzoyl peroxide, adapalene and azelaic acid (more on that below). The dermatologists we spoke to noted a few other considerations when using skin care products on acne-prone skin. For this article, I spoke to dermatologists to find out everything you should know about acne-prone skin care.

Persons: It’s, Eileen Deignan, Graber, La, Posay, Tracy Evans, Stevenson, Evans, Zoe Malin, Zoe Malin Dr, Caren Campbell, Differin, Malin, Ashley Morris, Mario, Mario Badescu, Posay’s, Campbell —, blackheads, La Roche, kaolin, Morris, who’s, ”, Lindsey Bordone, Cetaphil, Erum Ilyas, Baume, Supergoop’s sunscreens, Dr, Mary Stevenson, you’re, Deignan, “, ” Evans, dermatologists, TikTok Organizations: Dermatology, NBC, Neutrogena, Emerson Hospital, of Boston, Columbia University Medical Center, La Roche, NYU Langone Health’s, of Dermatology, Facebook, Twitter Locations: U.S, Posay, California, Neutrogena, La

☆ Bear market is coming in 2025, warns David Roche, but the Fed will step in before it turns 'draconian'
▼ + stars: | 2024-08-12 | by ( Dylan Butts | ) www.cnbc.com time to read: +1 min

Veteran investor David Roche expects a bear market in 2025 caused by smaller-than-expected rate cuts, a slowing U.S. economy and an artificial intelligence bubble. "I think [a bear market] is probably coming, but probably in 2025. Roche expects the Fed to resist reducing rates to the market's desired 3.50%. "The second thing is that profits [won't] fulfill expectations, because the economy is going to be slowing," Roche warned. The third factor Roche expects will lead to a bear market is the AI sector.

Persons: David Roche, CNBC's, Roche Organizations: Quantum Strategy, U.S, Presidential

☆ Bear market is probably coming in 2025, veteran investor David Roche says
▼ + stars: | 2024-08-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBear market is probably coming in 2025, veteran investor David Roche saysDavid Roche, strategist at Quantum Strategy, discusses the two factors that will cause it.

Persons: David Roche Organizations: Quantum

☆ The yen carry trade will still be 'highly profitable' in 2 years' time, David Roche says
▼ + stars: | 2024-08-12 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe yen carry trade will still be 'highly profitable' in 2 years' time, David Roche saysDavid Roche, strategist at Quantum Strategy, discusses the yen carry trade and global markets.

Persons: David Roche Organizations: Quantum

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Novo Nordisk shares dip as Wegovy maker posts earnings miss, cuts operating profit outlook
▼ + stars: | 2024-08-07 | by ( Sophie Kiderlin | In | ) www.cnbc.com time to read: +3 min

Novo Nordisk Wegovy manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 8, 2024. EBIT — earnings before interest and tax — came in at 25.93 billion Danish kroner in the second quarter, which was also below the LSEG forecast of 26.86 billion Danish kroner. Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook. Novo Nordisk CEO Lars Fruergaard Jørgensen on Wednesday said that the company was expecting "attractive growth" in the coming months. The drug was approved in China in the second quarter, opening it for sale in the world's second largest economy.

Persons: Jakub Porzycki, —, Wegovy, Lars Fruergaard Jørgensen, CNBC's, Roche, Jørgensen Organizations: Novo Nordisk Wegovy, Novo Nordisk, Getty, Nordisk Locations: Krakow, Poland, London, China

☆ Swiss SIX exchange says trading halted due to technical issues
▼ + stars: | 2024-07-31 | by ( ) www.cnbc.com time to read: 1 min

Four Chinese companies raised about $1.5 billion in July by issuing shares on the Six Swiss Exchange via a new China stock connect program. Switzerland's stock exchange SIX said trading had been halted on Wednesday morning across all products until further notice due to technical problems. The Swiss stock exchange is home to companies including Nestle , Roche and UBS . "Market data and index data is not being disseminated at the moment and we are investigating the cause and trying to solve," a spokesperson at SIX told Reuters. "Trading was not affected, but we had to halt trading in Switzerland due to equal treatment of market participants."

Organizations: Six Swiss, Nestle, Roche, UBS, SIX, Reuters Locations: China, Swiss, Switzerland

☆ Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
▼ + stars: | 2024-07-29 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. However, in an FT interview published earlier Monday, CEO Thomas Schinecker indicated that the firm's first obesity drug could come to market "significantly faster than people are expecting," potentially by 2028. Both CT-388 and CT-996 were acquired as part of Roche's purchase of U.S. biotech company Carmot Therapeutics, which completed in January. The promising results could see Roche emerge as a potential rival to obesity drug pioneers Novo Nordisk and Eli Lilly. Schinecker told CNBC last week that he expects the company to eventually offer a suite of obesity medications.

Persons: Roche, Nordisk's Wegovy, Eli Lilly, Thomas Schinecker, Teresa Graham, Roche's, Schinecker Organizations: Nordisk's, CNBC, Roche Pharmaceuticals, Carmot Therapeutics, Novo Nordisk Locations: U.S

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ Bristol Myers surges 10%, its biggest increase since 2008, after boosting profit forecast
▼ + stars: | 2024-07-26 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +3 min

Bristol Myers boosted its adjusted earnings for the year to between 60 and 90 cents a share, up 20 cents from its last forecast. AdvertisementOf Bristol Myers' existing drugs, Eliquis saw a 7% increase in sales year-over-year. Cancer drug Opdivo and blood cancer treatment Revlimid also saw promising results and beat quarterly sales estimates. The company reiterated its plan to cut $1.5 billion in costs by 2025, which was announced at its last quarterly earnings call. Bristol Myers is only the latest of a host of other drugmakers to raise their earnings guidance this week.

Persons: Myers, —, Bristol Myers, Christopher Boerner, Eliquis, Revlimid, David Elkins, Boerner, AbbVie Organizations: Bristol, Myers Squibb, Service, Cancer, FDA, AstraZeneca, Roche, Sanofi Locations: Bristol

☆ Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager says
▼ + stars: | 2024-07-26 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

Weight loss drugs have drawn investor interest and shaken up other sectors in the past year or so. Novo Nordisk and Eli Lilly were two early winners of this trend, as their drugs dominate the weight loss drug market. Yuri Khodjamirian, fund manager at Tema ETFs, said both companies are a "very powerful duopoly." They're a lot more risky than the bigger ones who already have drugs on the market," Khodjamirian said. Tema ETFs offers actively managed exchange-traded funds, with a focus on health care and life sciences.

Persons: Eli Lilly, Yuri Khodjamirian, Goldman Sachs, Khodjamirian, Roche Organizations: Novo Nordisk, Tema, CNBC, Zealand Pharma, Viking Therapeutics, Tema Oncology, Mental Health Locations: Tema

☆ Novo Nordisk's Wegovy wins EU backing for reducing heart risks
▼ + stars: | 2024-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand the medicine's use to include reducing the rise of serious heart events in overweight and obese adults. "The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events." Novo Nordisk said it expects to implement the label update within a month. The company's CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential."

Persons: Wegovy, —, Martin Holst Lange, Roche, Thomas Schinecker Organizations: Novo Nordisk, Novo, European Medical Agency, U.S . Food, Drug Administration Locations: Danish, U.S, Swiss

☆ Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
▼ + stars: | 2024-07-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential." "We do believe we have two next generation GLP-1/GIPs that have a best in disease potential," he said of the obesity drugs. GLP-1s, or glucagon-like peptide 1 agonists, are a group of drugs used to treat diabetes and obesity. They form the basis of weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Persons: Roche, Thomas Schinecker, Schinecker, CNBC's, Nordisk's Wegovy, Eli Lilly's Zepbound Organizations: Nordisk's

Search resuls for: "Roche"

25 mentions found